Abstract Disease Overview Diffuse large B‐cell lymphoma (DLBCL) is the most common
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …

Uniformly adopted response criteria are essential for assessment of therapies incorporating
conventional chemotherapy and chemoimmunotherapy regimens. Recently …

Background Patients with relapsed or refractory diffuse large B-cell lymphoma who are
ineligible for autologous stem-cell transplantation have poor outcomes and few treatment …

PURPOSE Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell
lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus …

Abstract Tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal
antibody, combined with the immunomodulatory drug lenalidomide was clinically active with …

Background The identification of oncogenic mutations in diffuse large B-cell lymphoma
(DLBCL) has led to the development of drugs that target essential survival pathways, but …

Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R …

B cell lymphomas are cancers that arise from cells that depend on numerous highly
orchestrated interactions with immune and stromal cells in the course of normal …

Few patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) achieve
prolonged disease-free survival. Blinatumomab, a bispecific T-cell engaging antibody …

Purpose Lenalidomide has significant single-agent activity in relapsed diffuse large B-cell
lymphoma (DLBCL). We demonstrated that lenalidomide can be safely combined with R …